Compugen (CGEN, Financial) experienced a significant stock fluctuation, with a sharp decline of 5.03%. The stock is currently priced at $1.51 per share with a trading volume of 229,568 shares. This represents a turnover rate of 0.26% and a price volatility of 5.58%.
Recent financial reports reveal that Compugen achieved a revenue of $17.13 million, a net profit of $1.28 million, and an earnings per share of $0.01. The gross profit was $13.53 million, resulting in a price-to-earnings ratio of 78.78. Among the three institutions that rated the stock, all recommended a "buy," with no hold or sell recommendations.
In the broader biotechnology sector, a general downturn of 1.06% was observed. While some related stocks such as 60 Degrees Pharmaceuticals and Psyence Biomedical showed notable gains, others like Molecular Templates and Pulmatrix displayed high trading activity with turnover rates of 4429.09% and 385.63% respectively.
Compugen Ltd is a clinical-stage company known for its therapeutic discovery and development. It leverages predictive computational discovery capabilities to identify novel drug targets and biological pathways for developing cancer immunotherapy treatments. Its pipeline includes clinical-stage projects like COM701, COM902, and bapotulimab, focusing on immune checkpoints identified through computation.
